Publications by authors named "Kyle Wathen"

Claim this Profile
A
A platform trial approach to proof-of-concept (POC) studies in autism spectrum disorder: Autism spectrum POC initiative (ASPI).
J Kyle Wathen, Shyla Jagannatha, Seth Ness, Abigail Bangerter, Gahan Pandina

Contemp Clin Trials Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Who wants to go first? A simulation study of accrual in a stand-alone trial versus starting a platform trial.
Kristine Broglio, Julia Niewczas, Kyle Wathen

Contemp Clin Trials· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials.
Jay J H Park, Behnam Sharif, Ofir Harari, Louis Dron, Anna Heath, J Kyle Wathen

JAMA Netw Open· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: ASPI: a public-private partnership to develop treatments for autism.
Seth Ness, Gahan Pandina, Shyla Jagannatha, Kyle Wathen, Abigail Bangerter

Nat Rev Drug Discov· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASPI: a public-private partnership to develop treatments for autism.
Seth Ness, Gahan Pandina, Shyla Jagannatha, Kyle Wathen, Abigail Bangerter

Nat Rev Drug Discov· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simulation study of outcome adaptive randomization in multi-arm clinical trials.
J Kyle Wathen, Peter F Thall

Clin Trials· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.
Scott M Schuetze, J Kyle Wathen, David R Lucas, Edwin Choy, Brian L Samuels

Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive Design: Results of 2012 Survey on Perception and Use.
Caroline Claire Morgan, Susan Huyck, Martin Jenkins, Li Chen, Alun Bedding, J Kyle Wathen

Ther Innov Regul Sci· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.
E J Freireich, B Lichtiger, G Mattiuzzi, F Martinez, V Reddy, J Kyle Wathen

Leukemia· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Martee L Hensley, J Kyle Wathen, Robert G Maki, Dejka M Araujo, Gregory Sutton

Cancer· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Elizabeth Fox, Shreyaskumar Patel, J Kyle Wathen, Scott Schuetze, Sant Chawla

Oncologist· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.
Simrit Parmar, Borje S Andersson, Daniel Couriel, Mark F Munsell, Marcelo Fernandez-Vina, J Kyle Wathen

J Clin Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
Rashmi Chugh, J Kyle Wathen, Shreyaskumar R Patel, Robert G Maki, Paul A Meyers

Clin Cancer Res· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
Rashmi Chugh, J Kyle Wathen, Robert G Maki, Robert S Benjamin, Shreyaskumar R Patel

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality.
Donald Berry, J Kyle Wathen, Margaret Newell

Clin Trials· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian adaptive model selection for optimizing group sequential clinical trials.
J Kyle Wathen, Peter F Thall

Stat Med· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accounting for patient heterogeneity in phase II clinical trials.
J Kyle Wathen, Peter F Thall, John D Cook, Elihu H Estey

Stat Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian designs to account for patient heterogeneity in phase II clinical trials.
Peter F Thall, J Kyle Wathen

Curr Opin Oncol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Robert G Maki, J Kyle Wathen, Shreyaskumar R Patel, Dennis A Priebat, Scott H Okuno

J Clin Oncol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Bayesian adaptive randomisation in clinical trials.
Peter F Thall, J Kyle Wathen

Eur J Cancer· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous Bayesian adaptive randomization based on event times with covariates.
Ying Kuen Cheung, Lurdes Y T Inoue, J Kyle Wathen, Peter F Thall

Stat Med· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments.
Peter F Thall, J Kyle Wathen

Stat Med· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAX6 suppresses growth of human glioblastoma cells.
Yi-Hong Zhou, Xiaosong Wu, Fang Tan, Yue-Xi Shi, Tricia Glass, Kyle Wathen

J Neurooncol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Peter F Thall, J Kyle Wathen, B Nebiyou Bekele, Richard E Champlin, Laurence H Baker

Stat Med· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
Bailu Peng, Jason B Fleming, Tara Breslin, Ana M Grau, Shuichi Fojioka, Kyle Wathen

Clin Cancer Res· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis